$47.98
+0.0000%Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Last Annual Value
25.35M
3-Year CAGR
33%
5-Year CAGR
44%
10-Year CAGR
20%
| Company | shares-outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Tourmaline Bio, Inc. NASDAQ:TRML | 25.35M | 74.8% | 18.4% | N/A | |
![]() Amylyx Pharmaceuticals, Inc. NASDAQ:AMLX | 94.57M | 10.6% | 10.3% | N/A | |
![]() Dianthus Therapeutics, Inc. NASDAQ:DNTH | 37.79M | 94.3% | 61.6% | 32.8% | |
![]() Enliven Therapeutics, Inc. NASDAQ:ELVN | 56.66M | 16.8% | 48.6% | N/A | |
![]() ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | 87.79M | 19.5% | 18.3% | N/A | |
![]() Precigen, Inc. NASDAQ:PGEN | 304.71M | 7.6% | 9.0% | 10.0% | |
![]() Relay Therapeutics, Inc. NASDAQ:RLAY | 171.59M | 11.9% | 12.5% | N/A | |
![]() Syndax Pharmaceuticals, Inc. NASDAQ:SNDX | 86.63M | 7.2% | 10.7% | 19.5% | |
![]() Terns Pharmaceuticals, Inc. NASDAQ:TERN | 93.17M | 9.3% | 29.8% | N/A |
Continue your TRML research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.